http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 23 Apr 2026 07:30:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+to+Participate+and+Present+at+the+2nd+Neuroscience+Innovation+Partnering+and+Licensing+Summit/26354651.html <p align="justify">CALGARY, Alberta, April 23, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF</strong>), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively <strong>“Marvel” </strong>or the<strong> “Company”</strong>), a biotechnology company developing novel therapies for autism spectrum disorder, related neurological and neurodevelopmental disorders, today announces it will participate in the <strong>2nd Neuroscience Innovation Partnering &amp; Licensing Summit</strong> on April 28-29th at the Revere Hotel Boston Common 200 Stuart St, in Boston, <strong> </strong>Massachusetts, United States. The company will present at 11.15 am EST on April 29th and invites shareholders, investors, stakeholders, partners, interested parties and the public to view http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+to+Participate+and+Present+at+the+2nd+Neuroscience+Innovation+Partnering+and+Licensing+Summit/26354651.html Thu, 23 Apr 2026 07:30:00 -0400 A.36078215 MBCOF MRVL O.02555813 O.46356335 http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+to+Participate+and+Present+at+the+2nd+Neuroscience+Innovation+Partnering+and+Licensing+Summit/26354651.html <p align="justify">CALGARY, Alberta, April 23, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF</strong>), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively <strong>“Marvel” </strong>or the<strong> “Company”</strong>), a biotechnology company developing novel therapies for autism spectrum disorder, related neurological and neurodevelopmental disorders, today announces it will participate in the <strong>2nd Neuroscience Innovation Partnering &amp; Licensing Summit</strong> on April 28-29th at the Revere Hotel Boston Common 200 Stuart St, in Boston, <strong> </strong>Massachusetts, United States. The company will present at 11.15 am EST on April 29th and invites shareholders, investors, stakeholders, partners, interested parties and the public to view http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+to+Participate+and+Present+at+the+2nd+Neuroscience+Innovation+Partnering+and+Licensing+Summit/26354651.html Thu, 23 Apr 2026 07:30:00 -0400 A.36078215 MBCOF MRVL O.02555813 O.46356335 http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+to+Participate+and+Present+at+the+2nd+Neuroscience+Innovation+Partnering+and+Licensing+Summit/26354651.html <p align="justify">CALGARY, Alberta, April 23, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF</strong>), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively <strong>“Marvel” </strong>or the<strong> “Company”</strong>), a biotechnology company developing novel therapies for autism spectrum disorder, related neurological and neurodevelopmental disorders, today announces it will participate in the <strong>2nd Neuroscience Innovation Partnering &amp; Licensing Summit</strong> on April 28-29th at the Revere Hotel Boston Common 200 Stuart St, in Boston, <strong> </strong>Massachusetts, United States. The company will present at 11.15 am EST on April 29th and invites shareholders, investors, stakeholders, partners, interested parties and the public to view http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+to+Participate+and+Present+at+the+2nd+Neuroscience+Innovation+Partnering+and+Licensing+Summit/26354651.html Thu, 23 Apr 2026 07:30:00 -0400 A.36078215 MBCOF MRVL O.02555813 O.46356335 http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+to+Participate+and+Present+at+the+2nd+Neuroscience+Innovation+Partnering+and+Licensing+Summit/26354651.html <p align="justify">CALGARY, Alberta, April 23, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF</strong>), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively <strong>“Marvel” </strong>or the<strong> “Company”</strong>), a biotechnology company developing novel therapies for autism spectrum disorder, related neurological and neurodevelopmental disorders, today announces it will participate in the <strong>2nd Neuroscience Innovation Partnering &amp; Licensing Summit</strong> on April 28-29th at the Revere Hotel Boston Common 200 Stuart St, in Boston, <strong> </strong>Massachusetts, United States. The company will present at 11.15 am EST on April 29th and invites shareholders, investors, stakeholders, partners, interested parties and the public to view http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+to+Participate+and+Present+at+the+2nd+Neuroscience+Innovation+Partnering+and+Licensing+Summit/26354651.html Thu, 23 Apr 2026 07:30:00 -0400 A.36078215 MBCOF MRVL O.02555813 O.46356335 http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+to+Participate+and+Present+at+the+2nd+Neuroscience+Innovation+Partnering+and+Licensing+Summit/26354651.html <p align="justify">CALGARY, Alberta, April 23, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF</strong>), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively <strong>“Marvel” </strong>or the<strong> “Company”</strong>), a biotechnology company developing novel therapies for autism spectrum disorder, related neurological and neurodevelopmental disorders, today announces it will participate in the <strong>2nd Neuroscience Innovation Partnering &amp; Licensing Summit</strong> on April 28-29th at the Revere Hotel Boston Common 200 Stuart St, in Boston, <strong> </strong>Massachusetts, United States. The company will present at 11.15 am EST on April 29th and invites shareholders, investors, stakeholders, partners, interested parties and the public to view http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+to+Participate+and+Present+at+the+2nd+Neuroscience+Innovation+Partnering+and+Licensing+Summit/26354651.html Thu, 23 Apr 2026 07:30:00 -0400 A.36078215 MBCOF MRVL O.02555813 O.46356335 http://www.streetinsider.com/Globe+Newswire/Marvel+Biosciences+to+Participate+and+Present+at+the+2nd+Neuroscience+Innovation+Partnering+and+Licensing+Summit/26354651.html <p align="justify">CALGARY, Alberta, April 23, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF</strong>), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively <strong>“Marvel” </strong>or the<strong> “Company”</strong>), a biotechnology company developing novel therapies for autism spectrum disorder, related neurological and neurodevelopmental disorders, today announces it will participate in the <strong>2nd Neuroscience Innovation Partnering &amp; Licensing Summit</strong> on April 28-29th at the Revere Hotel Boston Common 200 Stuart St, in Boston, <strong> </strong>Massachusetts, United States. The company will present at 11.15 am EST on April 29th and invites shareholders, investors, stakeholders, partners, interested parties and the public to view http://www.streetinsider.com/Globe+Newswire/Marvel+Biosciences+to+Participate+and+Present+at+the+2nd+Neuroscience+Innovation+Partnering+and+Licensing+Summit/26354651.html Thu, 23 Apr 2026 07:30:00 -0400 A.36078215 MBCOF MRVL O.02555813 O.46356335 http://www.streetinsider.com/Globe+Newswire/Marvel+Biosciences+to+Participate+and+Present+at+the+2nd+Neuroscience+Innovation+Partnering+and+Licensing+Summit/26354651.html <p align="justify">CALGARY, Alberta, April 23, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF</strong>), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively <strong>“Marvel” </strong>or the<strong> “Company”</strong>), a biotechnology company developing novel therapies for autism spectrum disorder, related neurological and neurodevelopmental disorders, today announces it will participate in the <strong>2nd Neuroscience Innovation Partnering &amp; Licensing Summit</strong> on April 28-29th at the Revere Hotel Boston Common 200 Stuart St, in Boston, <strong> </strong>Massachusetts, United States. The company will present at 11.15 am EST on April 29th and invites shareholders, investors, stakeholders, partners, interested parties and the public to view http://www.streetinsider.com/Globe+Newswire/Marvel+Biosciences+to+Participate+and+Present+at+the+2nd+Neuroscience+Innovation+Partnering+and+Licensing+Summit/26354651.html Thu, 23 Apr 2026 07:30:00 -0400 A.36078215 MBCOF MRVL O.02555813 O.46356335 http://www.streetinsider.com/Globe+Newswire/Marvel+Biosciences+to+Participate+and+Present+at+the+2nd+Neuroscience+Innovation+Partnering+and+Licensing+Summit/26354651.html <p align="justify">CALGARY, Alberta, April 23, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF</strong>), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively <strong>“Marvel” </strong>or the<strong> “Company”</strong>), a biotechnology company developing novel therapies for autism spectrum disorder, related neurological and neurodevelopmental disorders, today announces it will participate in the <strong>2nd Neuroscience Innovation Partnering &amp; Licensing Summit</strong> on April 28-29th at the Revere Hotel Boston Common 200 Stuart St, in Boston, <strong> </strong>Massachusetts, United States. The company will present at 11.15 am EST on April 29th and invites shareholders, investors, stakeholders, partners, interested parties and the public to view http://www.streetinsider.com/Globe+Newswire/Marvel+Biosciences+to+Participate+and+Present+at+the+2nd+Neuroscience+Innovation+Partnering+and+Licensing+Summit/26354651.html Thu, 23 Apr 2026 07:30:00 -0400 A.36078215 MBCOF MRVL O.02555813 O.46356335 http://www.streetinsider.com/Globe+Newswire/Marvel+Biosciences+to+Participate+and+Present+at+the+2nd+Neuroscience+Innovation+Partnering+and+Licensing+Summit/26354651.html <p align="justify">CALGARY, Alberta, April 23, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF</strong>), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively <strong>“Marvel” </strong>or the<strong> “Company”</strong>), a biotechnology company developing novel therapies for autism spectrum disorder, related neurological and neurodevelopmental disorders, today announces it will participate in the <strong>2nd Neuroscience Innovation Partnering &amp; Licensing Summit</strong> on April 28-29th at the Revere Hotel Boston Common 200 Stuart St, in Boston, <strong> </strong>Massachusetts, United States. The company will present at 11.15 am EST on April 29th and invites shareholders, investors, stakeholders, partners, interested parties and the public to view http://www.streetinsider.com/Globe+Newswire/Marvel+Biosciences+to+Participate+and+Present+at+the+2nd+Neuroscience+Innovation+Partnering+and+Licensing+Summit/26354651.html Thu, 23 Apr 2026 07:30:00 -0400 A.36078215 MBCOF MRVL O.02555813 O.46356335 http://www.streetinsider.com/Globe+Newswire/Marvel+Biosciences+to+Participate+and+Present+at+the+2nd+Neuroscience+Innovation+Partnering+and+Licensing+Summit/26354651.html <p align="justify">CALGARY, Alberta, April 23, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF</strong>), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively <strong>“Marvel” </strong>or the<strong> “Company”</strong>), a biotechnology company developing novel therapies for autism spectrum disorder, related neurological and neurodevelopmental disorders, today announces it will participate in the <strong>2nd Neuroscience Innovation Partnering &amp; Licensing Summit</strong> on April 28-29th at the Revere Hotel Boston Common 200 Stuart St, in Boston, <strong> </strong>Massachusetts, United States. The company will present at 11.15 am EST on April 29th and invites shareholders, investors, stakeholders, partners, interested parties and the public to view http://www.streetinsider.com/Globe+Newswire/Marvel+Biosciences+to+Participate+and+Present+at+the+2nd+Neuroscience+Innovation+Partnering+and+Licensing+Summit/26354651.html Thu, 23 Apr 2026 07:30:00 -0400 A.36078215 MBCOF MRVL O.02555813 O.46356335 http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Identifies+Liquid+Formulations+for+Neurodevelopmental+Disorders/26320948.html <p align="justify">CALGARY, Alberta, April 16, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF</strong>), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively <strong>“Marvel” </strong>or the<strong> “Company”</strong>), a biotechnology company developing novel therapies for neurological and neurodevelopmental disorders, today announces it has identified two lead pediatric-friendly liquid formulations of its patented lead compound, MB-204.</p> <p align="justify">This work was supported by a National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) grant and focused on the design of a small-volume oral liquid formulation of MB-204. This formulation is particularly important for children http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Identifies+Liquid+Formulations+for+Neurodevelopmental+Disorders/26320948.html Thu, 16 Apr 2026 07:00:00 -0400 A.36078215 MBCOF MRVL O.02555813 O.46356335 http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Identifies+Liquid+Formulations+for+Neurodevelopmental+Disorders/26320948.html <p align="justify">CALGARY, Alberta, April 16, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF</strong>), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively <strong>“Marvel” </strong>or the<strong> “Company”</strong>), a biotechnology company developing novel therapies for neurological and neurodevelopmental disorders, today announces it has identified two lead pediatric-friendly liquid formulations of its patented lead compound, MB-204.</p> <p align="justify">This work was supported by a National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) grant and focused on the design of a small-volume oral liquid formulation of MB-204. This formulation is particularly important for children http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Identifies+Liquid+Formulations+for+Neurodevelopmental+Disorders/26320948.html Thu, 16 Apr 2026 07:00:00 -0400 A.36078215 MBCOF MRVL O.02555813 O.46356335 http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Identifies+Liquid+Formulations+for+Neurodevelopmental+Disorders/26320948.html <p align="justify">CALGARY, Alberta, April 16, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF</strong>), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively <strong>“Marvel” </strong>or the<strong> “Company”</strong>), a biotechnology company developing novel therapies for neurological and neurodevelopmental disorders, today announces it has identified two lead pediatric-friendly liquid formulations of its patented lead compound, MB-204.</p> <p align="justify">This work was supported by a National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) grant and focused on the design of a small-volume oral liquid formulation of MB-204. This formulation is particularly important for children http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Identifies+Liquid+Formulations+for+Neurodevelopmental+Disorders/26320948.html Thu, 16 Apr 2026 07:00:00 -0400 A.36078215 MBCOF MRVL O.02555813 O.46356335 http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Identifies+Liquid+Formulations+for+Neurodevelopmental+Disorders/26320948.html <p align="justify">CALGARY, Alberta, April 16, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF</strong>), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively <strong>“Marvel” </strong>or the<strong> “Company”</strong>), a biotechnology company developing novel therapies for neurological and neurodevelopmental disorders, today announces it has identified two lead pediatric-friendly liquid formulations of its patented lead compound, MB-204.</p> <p align="justify">This work was supported by a National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) grant and focused on the design of a small-volume oral liquid formulation of MB-204. This formulation is particularly important for children http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Identifies+Liquid+Formulations+for+Neurodevelopmental+Disorders/26320948.html Thu, 16 Apr 2026 07:00:00 -0400 A.36078215 MBCOF MRVL O.02555813 O.46356335 http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Identifies+Liquid+Formulations+for+Neurodevelopmental+Disorders/26320948.html <p align="justify">CALGARY, Alberta, April 16, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF</strong>), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively <strong>“Marvel” </strong>or the<strong> “Company”</strong>), a biotechnology company developing novel therapies for neurological and neurodevelopmental disorders, today announces it has identified two lead pediatric-friendly liquid formulations of its patented lead compound, MB-204.</p> <p align="justify">This work was supported by a National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) grant and focused on the design of a small-volume oral liquid formulation of MB-204. This formulation is particularly important for children http://www.streetinsider.com/Press+Releases/Marvel+Biosciences+Identifies+Liquid+Formulations+for+Neurodevelopmental+Disorders/26320948.html Thu, 16 Apr 2026 07:00:00 -0400 A.36078215 MBCOF MRVL O.02555813 O.46356335 http://www.streetinsider.com/Globe+Newswire/Marvel+Biosciences+Identifies+Liquid+Formulations+for+Neurodevelopmental+Disorders/26320948.html <p align="justify">CALGARY, Alberta, April 16, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF</strong>), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively <strong>“Marvel” </strong>or the<strong> “Company”</strong>), a biotechnology company developing novel therapies for neurological and neurodevelopmental disorders, today announces it has identified two lead pediatric-friendly liquid formulations of its patented lead compound, MB-204.</p> <p align="justify">This work was supported by a National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) grant and focused on the design of a small-volume oral liquid formulation of MB-204. This formulation is particularly important for children http://www.streetinsider.com/Globe+Newswire/Marvel+Biosciences+Identifies+Liquid+Formulations+for+Neurodevelopmental+Disorders/26320948.html Thu, 16 Apr 2026 07:00:00 -0400 A.36078215 MBCOF MRVL O.02555813 O.46356335 http://www.streetinsider.com/Globe+Newswire/Marvel+Biosciences+Identifies+Liquid+Formulations+for+Neurodevelopmental+Disorders/26320948.html <p align="justify">CALGARY, Alberta, April 16, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF</strong>), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively <strong>“Marvel” </strong>or the<strong> “Company”</strong>), a biotechnology company developing novel therapies for neurological and neurodevelopmental disorders, today announces it has identified two lead pediatric-friendly liquid formulations of its patented lead compound, MB-204.</p> <p align="justify">This work was supported by a National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) grant and focused on the design of a small-volume oral liquid formulation of MB-204. This formulation is particularly important for children http://www.streetinsider.com/Globe+Newswire/Marvel+Biosciences+Identifies+Liquid+Formulations+for+Neurodevelopmental+Disorders/26320948.html Thu, 16 Apr 2026 07:00:00 -0400 A.36078215 MBCOF MRVL O.02555813 O.46356335 http://www.streetinsider.com/Globe+Newswire/Marvel+Biosciences+Identifies+Liquid+Formulations+for+Neurodevelopmental+Disorders/26320948.html <p align="justify">CALGARY, Alberta, April 16, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF</strong>), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively <strong>“Marvel” </strong>or the<strong> “Company”</strong>), a biotechnology company developing novel therapies for neurological and neurodevelopmental disorders, today announces it has identified two lead pediatric-friendly liquid formulations of its patented lead compound, MB-204.</p> <p align="justify">This work was supported by a National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) grant and focused on the design of a small-volume oral liquid formulation of MB-204. This formulation is particularly important for children http://www.streetinsider.com/Globe+Newswire/Marvel+Biosciences+Identifies+Liquid+Formulations+for+Neurodevelopmental+Disorders/26320948.html Thu, 16 Apr 2026 07:00:00 -0400 A.36078215 MBCOF MRVL O.02555813 O.46356335 http://www.streetinsider.com/Globe+Newswire/Marvel+Biosciences+Identifies+Liquid+Formulations+for+Neurodevelopmental+Disorders/26320948.html <p align="justify">CALGARY, Alberta, April 16, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF</strong>), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively <strong>“Marvel” </strong>or the<strong> “Company”</strong>), a biotechnology company developing novel therapies for neurological and neurodevelopmental disorders, today announces it has identified two lead pediatric-friendly liquid formulations of its patented lead compound, MB-204.</p> <p align="justify">This work was supported by a National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) grant and focused on the design of a small-volume oral liquid formulation of MB-204. This formulation is particularly important for children http://www.streetinsider.com/Globe+Newswire/Marvel+Biosciences+Identifies+Liquid+Formulations+for+Neurodevelopmental+Disorders/26320948.html Thu, 16 Apr 2026 07:00:00 -0400 A.36078215 MBCOF MRVL O.02555813 O.46356335 http://www.streetinsider.com/Globe+Newswire/Marvel+Biosciences+Identifies+Liquid+Formulations+for+Neurodevelopmental+Disorders/26320948.html <p align="justify">CALGARY, Alberta, April 16, 2026 (GLOBE NEWSWIRE) -- <strong>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF</strong>), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively <strong>“Marvel” </strong>or the<strong> “Company”</strong>), a biotechnology company developing novel therapies for neurological and neurodevelopmental disorders, today announces it has identified two lead pediatric-friendly liquid formulations of its patented lead compound, MB-204.</p> <p align="justify">This work was supported by a National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) grant and focused on the design of a small-volume oral liquid formulation of MB-204. This formulation is particularly important for children http://www.streetinsider.com/Globe+Newswire/Marvel+Biosciences+Identifies+Liquid+Formulations+for+Neurodevelopmental+Disorders/26320948.html Thu, 16 Apr 2026 07:00:00 -0400 A.36078215 MBCOF MRVL O.02555813 O.46356335 http://www.streetinsider.com/Corporate+News/Marvel+Biosciences+secures+funding+for+autism+drug+trial+from+5+Horizons/26280277.html <p>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF) announced it secured financial and strategic support from 5 Horizons Ventures for its upcoming Phase I clinical trial of drug candidate MB-204, according to a company press release.</p> <p>Under the partnership terms, 5 Horizons Ventures will contribute funding equivalent to 15% of Marvel's contract research organization costs associated with the Phase I clinical trial of MB-204. The company described this as non-dilutive support designed to reduce upfront capital requirements.</p> <p>The Phase I trial is expected to commence in the second quarter of 2026 and will evaluate the safety, tolerability, and pharmacokinetics of MB-204 in http://www.streetinsider.com/Corporate+News/Marvel+Biosciences+secures+funding+for+autism+drug+trial+from+5+Horizons/26280277.html Tue, 07 Apr 2026 12:26:34 -0400 A.06822034 A.36078215 MBCOF MRVL O.02555813 O.20026344 O.46356335 http://www.streetinsider.com/Corporate+News/Marvel+Biosciences+secures+funding+for+autism+drug+trial+from+5+Horizons/26280277.html <p>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF) announced it secured financial and strategic support from 5 Horizons Ventures for its upcoming Phase I clinical trial of drug candidate MB-204, according to a company press release.</p> <p>Under the partnership terms, 5 Horizons Ventures will contribute funding equivalent to 15% of Marvel's contract research organization costs associated with the Phase I clinical trial of MB-204. The company described this as non-dilutive support designed to reduce upfront capital requirements.</p> <p>The Phase I trial is expected to commence in the second quarter of 2026 and will evaluate the safety, tolerability, and pharmacokinetics of MB-204 in http://www.streetinsider.com/Corporate+News/Marvel+Biosciences+secures+funding+for+autism+drug+trial+from+5+Horizons/26280277.html Tue, 07 Apr 2026 12:26:34 -0400 A.06822034 A.36078215 MBCOF MRVL O.02555813 O.20026344 O.46356335 http://www.streetinsider.com/Corporate+News/Marvel+Biosciences+secures+funding+for+autism+drug+trial+from+5+Horizons/26280277.html <p>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF) announced it secured financial and strategic support from 5 Horizons Ventures for its upcoming Phase I clinical trial of drug candidate MB-204, according to a company press release.</p> <p>Under the partnership terms, 5 Horizons Ventures will contribute funding equivalent to 15% of Marvel's contract research organization costs associated with the Phase I clinical trial of MB-204. The company described this as non-dilutive support designed to reduce upfront capital requirements.</p> <p>The Phase I trial is expected to commence in the second quarter of 2026 and will evaluate the safety, tolerability, and pharmacokinetics of MB-204 in http://www.streetinsider.com/Corporate+News/Marvel+Biosciences+secures+funding+for+autism+drug+trial+from+5+Horizons/26280277.html Tue, 07 Apr 2026 12:26:34 -0400 A.06822034 A.36078215 MBCOF MRVL O.02555813 O.20026344 O.46356335 http://www.streetinsider.com/Corporate+News/Marvel+Biosciences+secures+funding+for+autism+drug+trial+from+5+Horizons/26280277.html <p>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF) announced it secured financial and strategic support from 5 Horizons Ventures for its upcoming Phase I clinical trial of drug candidate MB-204, according to a company press release.</p> <p>Under the partnership terms, 5 Horizons Ventures will contribute funding equivalent to 15% of Marvel's contract research organization costs associated with the Phase I clinical trial of MB-204. The company described this as non-dilutive support designed to reduce upfront capital requirements.</p> <p>The Phase I trial is expected to commence in the second quarter of 2026 and will evaluate the safety, tolerability, and pharmacokinetics of MB-204 in http://www.streetinsider.com/Corporate+News/Marvel+Biosciences+secures+funding+for+autism+drug+trial+from+5+Horizons/26280277.html Tue, 07 Apr 2026 12:26:34 -0400 A.06822034 A.36078215 MBCOF MRVL O.02555813 O.20026344 O.46356335 http://www.streetinsider.com/Corporate+News/Marvel+Biosciences+secures+funding+for+autism+drug+trial+from+5+Horizons/26280277.html <p>Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF) announced it secured financial and strategic support from 5 Horizons Ventures for its upcoming Phase I clinical trial of drug candidate MB-204, according to a company press release.</p> <p>Under the partnership terms, 5 Horizons Ventures will contribute funding equivalent to 15% of Marvel's contract research organization costs associated with the Phase I clinical trial of MB-204. The company described this as non-dilutive support designed to reduce upfront capital requirements.</p> <p>The Phase I trial is expected to commence in the second quarter of 2026 and will evaluate the safety, tolerability, and pharmacokinetics of MB-204 in http://www.streetinsider.com/Corporate+News/Marvel+Biosciences+secures+funding+for+autism+drug+trial+from+5+Horizons/26280277.html Tue, 07 Apr 2026 12:26:34 -0400 A.06822034 A.36078215 MBCOF MRVL O.02555813 O.20026344 O.46356335